REGN Regeneron Pharmaceuticals (REGN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000872589
Congress · 2Form 144 · 6
Insider buyers, 180 days
0
Funds added, last quarter
615
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $14.5M priced
What the filings say about REGN
Insiders, 180 days
-$6.7M net sold
5 sellers · 67% of sales under a 10b5-1 plan
Congress, 1 year
2 bought · 1 sold
Latest: sale, 2026-05-15
Planned sales (Form 144), 90 days
$6.5M
6 notices
Regeneron Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, REGENERON PHARMACEUTICALS, INC. insiders sold a net $6.7M of stock across 1,380 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 145 earlier Form 4 trades (code P or S) here by this insider (145 sales), the last on Aug 14, 2024.
- The trade is 0.0% of the 51,974 shares held after it.
- No other insider sold within 30 days.
- 615 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Scientific Officer MURPHY ANDREW J sold about $4.5K of REGN under a 10b5-1 plan on Oct 14, 2026; 615 funds added in the latest 13F quarter.Context
- 145 earlier Form 4 trades (code P or S) here by this insider (145 sales), the last on Aug 14, 2024.
- The trade is 0.1% of the 51,939 shares held after it.
- No other insider sold within 30 days.
- 615 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Scientific Officer MURPHY ANDREW J sold about $26.5K of REGN under a 10b5-1 plan on Oct 14, 2026; 615 funds added in the latest 13F quarter.Context
- 145 earlier Form 4 trades (code P or S) here by this insider (145 sales), the last on Aug 14, 2024.
- The trade is 0.0% of the 51,923 shares held after it.
- No other insider sold within 30 days.
- 615 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Scientific Officer MURPHY ANDREW J sold about $12.1K of REGN under a 10b5-1 plan on Oct 14, 2026; 615 funds added in the latest 13F quarter.Context
- 145 earlier Form 4 trades (code P or S) here by this insider (145 sales), the last on Aug 14, 2024.
- The trade is 0.0% of the 51,899 shares held after it.
- No other insider sold within 30 days.
- 615 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Scientific Officer MURPHY ANDREW J sold about $18.2K of REGN under a 10b5-1 plan on Oct 14, 2026; 615 funds added in the latest 13F quarter.Context
- 145 earlier Form 4 trades (code P or S) here by this insider (145 sales), the last on Aug 14, 2024.
- The trade is 0.0% of the 51,885 shares held after it.
- No other insider sold within 30 days.
- 615 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Scientific Officer MURPHY ANDREW J sold about $10.6K of REGN under a 10b5-1 plan on Oct 14, 2026; 615 funds added in the latest 13F quarter.1,380 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$6.7M over 180 days
-$6.5M over 90 days
below 81% of Pharma & Biotech
Congress
2 members bought in the last year
more than 76% of Pharma & Biotech
Funds
615 funds bought in last quarter
more than 98% of Pharma & Biotech
Revenue
+1.0% year over year
below 51% of Pharma & Biotech
Margin
31.4% net margin
more than 91% of Pharma & Biotech
Buybacks
$2.0B repurchased, FY to 2026-06-30
more than 98% of Pharma & Biotech
Short interest
2.2% of the float short (float per yahoo 2026-10-26) · 2.5 days to cover · settled 2026-09-30
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 15Co-Chief Scientific Officer MURPHY ANDREW J sold $3.2M under a 10b5-1 plan (Oct 14)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 14Officer MURPHY ANDREW J filed to sell $3.2M by Oct 14 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch REGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+38.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns REGN: institutional holders (13F)
13F holdings, latest reported quarter
9,113,506 sh
$5.7B
6,629,759 sh
$4.1B
4,871,137 sh
$3.0B
4,834,688 sh
$3.0B
3,940,665 sh
$2.5B
Congress trades in REGN
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-05-15 · disclosed 24 days later
$1,001 - $15,000
Bought 2026-02-12 · disclosed 28 days later
$1,001 - $15,000
Bought 2025-11-18 · disclosed 27 days later
$1,001 - $15,000
Bought 2025-05-15 · disclosed 25 days later
$1,001 - $15,000
Sold 2025-04-10 · disclosed 44 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
REGN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MURPHY ANDREW J
Filed 2026-10-14
$3.2M
McCourt Marion
Filed 2026-09-03
$969.3K
Guarini Kathryn
Filed 2026-09-02
$340.0K
McCourt Marion
Filed 2026-09-02
$1.0M
Guarini Kathryn
Filed 2026-08-10
$320.0K
REGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VanEck Biotech ETF
$24.6M position · as of 2026-06-30
6.2%
Invesco Biotechnology & Genome ETF
$15.4M position · as of 2026-07-31
5.5%
Invesco Nasdaq Biotechnology ETF
$3.4M position · as of 2026-05-31
5.1%
iShares Biotechnology ETF
$445.9M position · as of 2026-06-30
4.9%
Longleaf Partners Global Fund
$33.0M position · as of 2026-06-30
4.8%
Longleaf Partners Fund
$49.8M position · as of 2026-06-30
4.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
255 registered trials, 124 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
46
Phase 1
18 active
59
Phase 2
27 active
60
Phase 3
37 active
7
Phase 4
4 active
45
Not applicable
10 active
38
Multi-phase
28 active
What changed recently
An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossifican
2026-10-27 · Temporarily Not Available → Approved For Marketing
,
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Ste
2026-10-27 · Not Yet Recruiting → Recruiting
Phase 2
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Ca
2026-10-21 · Recruiting → Active Not Recruiting
Phase 1
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Bett
2026-10-17 · Not Yet Recruiting → Recruiting
Phase 4
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participa
2026-10-16 · Recruiting → Active Not Recruiting
Phase 2
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in
2026-10-09 · Completion moved 2028-12-10 → 2030-07-08
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
IGF::OT::IGF · 2017-09-30
$973.6M
Department Of Health And Human Services
IGF::OT::IGF - REGENERON OTHER TRANSACTION AUTHORITY (OTA) AWARD · 2017-09-21
$278.8M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Regeneron Pharmaceuticals, Inc. Pac
Cycle 2026 · $160K spent
$261.5K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Leonard S. Schleifer
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.3M
$39.0M
$7.7M
+60%
+101%
2024
$6.8M
-$37.7M
$6.1M
+47%
+56%
2023
$8.2M
$141.1M
$6.7M
+82%
+44%
2022
$7.0M
$98.8M
$8.1M
+49%
+39%
2021
$6.5M
$123.7M
$7.5M
+31%
+24%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $6.7M sold by insiders over 180 days, 615 funds added last quarter, 2 House member(s) bought in 12 months, disclosed weeks after the trade, $6.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
REGN financials
Revenue growth
+1.0%
XBRL, annual
Net margin
31.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$15.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM REGN
| FY Dec 2025 | $14.3B |
| FY Dec 2024 | $14.2B |
| FY Dec 2023 | $13.1B |
| FY Dec 2022 | $12.2B |
| FY Dec 2021 | $16.1B |
| Jun 2026 | $4.3B |
| Mar 2026 | $3.6B |
| Dec 2025 | $3.9B |
| Sep 2025 | $3.8B |
| Jun 2025 | $3.7B |
| Mar 2025 | $3.0B |
| Dec 2024 | $3.8B |
| Sep 2024 | $3.7B |
At each fiscal year end
Single quarter
Net margin, TTM
+27.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM REGN
| FY Dec 2025 | +31.4% |
| FY Dec 2024 | +31.1% |
| FY Dec 2023 | +30.1% |
| FY Dec 2022 | +35.6% |
| FY Dec 2021 | +50.2% |
| Jun 2026 | +30.2% |
| Mar 2026 | +20.2% |
| Dec 2025 | +21.7% |
| Sep 2025 | +38.9% |
| Jun 2025 | +37.9% |
| Mar 2025 | +26.7% |
| Dec 2024 | +24.2% |
| Sep 2024 | +36.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$3.8B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM REGN
| FY Dec 2025 | $4.1B |
| FY Dec 2024 | $3.7B |
| FY Dec 2023 | $3.9B |
| FY Dec 2022 | $4.4B |
| FY Dec 2021 | $6.5B |
| Jun 2026 | $572.8M |
| Mar 2026 | $848.3M |
| Dec 2025 | $922.0M |
| Sep 2025 | $1.4B |
| Jun 2025 | $925.4M |
| Mar 2025 | $815.8M |
| Dec 2024 | $1.1B |
| Sep 2024 | $1.0B |
At each fiscal year end
Single quarter
Debt to equity
0.11x
long-term 2026-06-30 plus current 2020-06-30 (73 months older than the period end); equity 2026-06-30
Debt to equity REGN
| FY Dec 2025 | 0.11x |
| FY Dec 2024 | 0.12x |
| FY Dec 2023 | 0.13x |
| FY Dec 2022 | 0.15x |
| FY Dec 2021 | 0.19x |
| Jun 2026 | 0.11x |
| Mar 2026 | 0.11x |
| Dec 2025 | 0.11x |
| Sep 2025 | 0.11x |
| Jun 2025 | 0.12x |
| Mar 2025 | 0.12x |
| Dec 2024 | 0.12x |
| Sep 2024 | 0.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
1.34x
TTM operating cash flow over long-term 2026-06-30 plus current 2020-06-30 (73 months older than the period end)
Cash flow to debt REGN
| FY Dec 2025 | 1.43x |
| FY Dec 2024 | 1.27x |
| FY Dec 2023 | 1.32x |
| FY Dec 2022 | 1.44x |
| FY Dec 2021 | 2.03x |
| Jun 2026 | 1.34x |
| Mar 2026 | 1.44x |
| Dec 2025 | 1.43x |
| Sep 2025 | 1.45x |
| Jun 2025 | 1.36x |
| Mar 2025 | 1.13x |
| Dec 2024 | 1.27x |
| Sep 2024 | 1.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+14.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity REGN
| FY Dec 2025 | +14.9% |
| FY Dec 2024 | +16.0% |
| FY Dec 2023 | +16.3% |
| FY Dec 2022 | +20.9% |
| FY Dec 2021 | +54.2% |
| Jun 2026 | +14.0% |
| Mar 2026 | +14.5% |
| Dec 2025 | +14.9% |
| Sep 2025 | +15.2% |
| Jun 2025 | +15.3% |
| Mar 2025 | +16.0% |
| Dec 2024 | +16.0% |
| Sep 2024 | +17.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+10.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets REGN
| FY Dec 2025 | +11.5% |
| FY Dec 2024 | +12.5% |
| FY Dec 2023 | +12.7% |
| FY Dec 2022 | +15.9% |
| FY Dec 2021 | +37.9% |
| Jun 2026 | +10.8% |
| Mar 2026 | +11.3% |
| Dec 2025 | +11.5% |
| Sep 2025 | +11.8% |
| Jun 2025 | +12.0% |
| Mar 2025 | +12.5% |
| Dec 2024 | +12.5% |
| Sep 2024 | +13.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+10.0%
operating income after a 16.2% effective tax rate, over long-term 2026-06-30 plus current 2020-06-30 (73 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital REGN
| FY Dec 2025 | +9.9% |
| FY Dec 2024 | +12.9% |
| FY Dec 2023 | +15.3% |
| FY Dec 2022 | +20.0% |
| FY Dec 2021 | +48.9% |
| Jun 2026 | +10.0% |
| Mar 2026 | +10.1% |
| Dec 2025 | +9.9% |
| Sep 2025 | +10.5% |
| Jun 2025 | +11.5% |
| Mar 2025 | +12.0% |
| Dec 2024 | +12.9% |
| Sep 2024 | +13.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+10.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed REGN
| FY Dec 2025 | +10.2% |
| FY Dec 2024 | +12.6% |
| FY Dec 2023 | +14.5% |
| FY Dec 2022 | +19.9% |
| FY Dec 2021 | +49.7% |
| Jun 2026 | +10.9% |
| Mar 2026 | +10.4% |
| Dec 2025 | +10.2% |
| Sep 2025 | +10.6% |
| Jun 2025 | +11.4% |
| Mar 2025 | +11.8% |
| Dec 2024 | +12.6% |
| Sep 2024 | +12.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
19.89x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing REGN
| FY Dec 2025 | 18.57x |
| FY Dec 2024 | 18.58x |
| FY Dec 2023 | 25.27x |
| FY Dec 2022 | 18.87x |
| FY Dec 2021 | 8.76x |
| Jun 2026 | 15.41x |
| Mar 2026 | 18.82x |
| Dec 2025 | 18.57x |
| Sep 2025 | 13.45x |
| Jun 2025 | 13.21x |
| Mar 2025 | 16.13x |
| Dec 2024 | 18.58x |
| Sep 2024 | 26.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value REGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield REGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
10.68x
P/E over trailing EPS growth of 2%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing REGN
| FY Dec 2025 | 2.20x |
| FY Dec 2024 | 1.81x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.06x |
| Jun 2026 | 8.27x |
| Mar 2026 | 4.30x |
| Dec 2025 | 2.20x |
| Sep 2025 | 3.91x |
| Jun 2025 | 2.55x |
| Mar 2025 | 1.00x |
| Dec 2024 | 1.81x |
| Sep 2024 | 1.70x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $14.3B | $14.2B | $13.1B | $12.2B |
| Operating income | $3.6B | $4.0B | $4.0B | $4.7B |
| Net income | $4.5B | $4.4B | $4.0B | $4.3B |
| EPS (diluted) | 41.48 | 38.34 | 34.77 | 38.22 |
| Operating cash flow | $5.0B | $4.4B | $4.6B | $5.0B |
| Cash | $3.1B | $2.5B | $2.7B | $3.1B |
| Long-term debt | $2.0B | $2.0B | $2.0B | $2.0B |
| Buybacks | $3.4B | $2.6B | $2.2B | $2.1B |
| Dividends paid | $370.3M | $0 | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
REGN Stock Sonar score 6/7 axes
Find similar shapesCompareREGN ranks highest on institutional and government (83rd percentile) and profitability (76th), and lowest on insider conviction (17th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
REGN filings, in plain words
Are Regeneron Pharmaceuticals insiders buying or selling REGN?
In the 180 days to 2026-10-27, Regeneron Pharmaceuticals insiders were net sellers, a net $6.7M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded REGN?
Yes. In the year to 2026-10-27, 2 House members disclosed buying REGN and 1 House member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-05-15.
Are there planned insider sales of REGN?
Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $6.5M of stock; the latest, by MURPHY ANDREW J, was filed 2026-10-14.
Read the full summary
In the 180 days to 2026-10-27, Regeneron Pharmaceuticals insiders were net sellers of REGN, a net $6.7M across purchases and sales reported on Form 4 by 5 sellers. 67% of the 45 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 2 members of Congress disclosed buying REGN and 1 member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-05-15. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $6.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
